SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


BioSyntech specialized in the development, manufacturing and commercialization of biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The company’s assets were acquired in 2010 by Piramal Healthcare Ltd.
BioSyntech
Laval, Quebec